Clinical Trial Update: Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on nemvaleukin alfa (ALKS 4230) used as monotherapy and in combination with pembrolizumab (ARTISTRY-3) in advanced solid tumors, focusing …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Nemvaleukin alfa (nemvaleukin alfa)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Mural Oncology, Inc | Conditions: Advanced Solid Tumor | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING